Trial Profile
A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs BMS 986179 (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Bristol-Myers Squibb
- 08 Mar 2024 This trial has been completed in Italy, According to European Clinical Trials Database record.
- 10 Mar 2023 The time frame of primary endpoints changed.
- 25 May 2022 Status changed from active, no longer recruiting to completed.